These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 28573524)

  • 1. Use of various gonadotropin and biosimilar formulations for in vitro fertilization cycles: results of a worldwide Web-based survey.
    Christianson MS; Shoham G; Tobler KJ; Zhao Y; Monseur B; Leong M; Shoham Z
    J Assist Reprod Genet; 2017 Aug; 34(8):1059-1066. PubMed ID: 28573524
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Effect of domestic highly purified urinary follicle stimulating hormone on outcomes of in vitro fertilization-embryo transfer in controlled ovarian stimulation].
    Ye H; Huang GN; Cao YX; Zhong Y; Huang YH; Zhu GJ; Zhou LM; Chen ZJ; Shi JZ; Zeng Y; Weng N; Huang XF; Yang J; Zhu YM; Li YP; Yi D; Zhuang GL
    Zhonghua Fu Chan Ke Za Zhi; 2013 Nov; 48(11):838-42. PubMed ID: 24444561
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recombinant follicle-stimulating hormone and recombinant luteinizing hormone versus recombinant follicle-stimulating hormone alone during GnRH antagonist ovarian stimulation in patients aged ≥35 years: a randomized controlled trial.
    Vuong TN; Phung HT; Ho MT
    Hum Reprod; 2015 May; 30(5):1188-95. PubMed ID: 25740882
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A mild ovarian stimulation strategy in women with poor ovarian reserve undergoing IVF: a multicenter randomized non-inferiority trial.
    Youssef MA; van Wely M; Al-Inany H; Madani T; Jahangiri N; Khodabakhshi S; Alhalabi M; Akhondi M; Ansaripour S; Tokhmechy R; Zarandi L; Rizk A; El-Mohamedy M; Shaeer E; Khattab M; Mochtar MH; van der Veen F
    Hum Reprod; 2017 Jan; 32(1):112-118. PubMed ID: 27836979
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-Müllerian hormone versus antral follicle count for defining the starting dose of FSH.
    Lan VT; Linh NK; Tuong HM; Wong PC; Howles CM
    Reprod Biomed Online; 2013 Oct; 27(4):390-9. PubMed ID: 23953069
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bye-bye urinary gonadotrophins? Recombinant FSH: a real progress in ovulation induction and IVF?
    Gleicher N; Vietzke M; Vidali A
    Hum Reprod; 2003 Mar; 18(3):476-82. PubMed ID: 12615810
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recombinant versus urinary gonadotrophin for ovarian stimulation in assisted reproductive technology cycles. A Cochrane review.
    van Wely M; Kwan I; Burt AL; Thomas J; Vail A; Van der Veen F; Al-Inany HG
    Hum Reprod Update; 2012; 18(2):111. PubMed ID: 22301671
    [No Abstract]   [Full Text] [Related]  

  • 8. Live birth rates after modified natural cycle compared with high-dose FSH stimulation using GnRH antagonists in poor responders.
    Lainas TG; Sfontouris IA; Venetis CA; Lainas GT; Zorzovilis IZ; Tarlatzis BC; Kolibianakis EM
    Hum Reprod; 2015 Oct; 30(10):2321-30. PubMed ID: 26307091
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Do poor-responder patients benefit from increasing the daily gonadotropin dose during controlled ovarian hyperstimulation for IVF?
    Haas J; Zilberberg E; Machtinger R; Kedem A; Hourvitz A; Orvieto R
    Gynecol Endocrinol; 2015 Jan; 31(1):79-82. PubMed ID: 25223892
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparison of outcomes from in vitro fertilization cycles stimulated with either recombinant luteinizing hormone (LH) or human chorionic gonadotropin acting as an LH analogue delivered as human menopausal gonadotropins, in subjects with good or poor ovarian reserve: a retrospective analysis.
    Dahan MH; Agdi M; Shehata F; Son W; Tan SL
    Eur J Obstet Gynecol Reprod Biol; 2014 Jan; 172():70-3. PubMed ID: 24314801
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Comparison of the efficiency between in-vitro maturation and in-vitro fertilization after early follicular phase GnRH agonist down-regulation in infertile women with polycystic ovary syndrome].
    Zhu RR; Xiao SQ; Zhao JZ; Lin J; Wang PY; Jin CC; Jin WM
    Zhonghua Fu Chan Ke Za Zhi; 2013 Nov; 48(11):833-7. PubMed ID: 24444560
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metformin reduces risk of ovarian hyperstimulation syndrome in patients with polycystic ovary syndrome during gonadotropin-stimulated in vitro fertilization cycles: a randomized, controlled trial.
    Palomba S; Falbo A; Carrillo L; Villani MT; Orio F; Russo T; Di Cello A; Cappiello F; Capasso S; Tolino A; Colao A; Mastrantonio P; La Sala GB; Zullo F; Cittadini E;
    Fertil Steril; 2011 Dec; 96(6):1384-1390.e4. PubMed ID: 21982727
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk of severe ovarian hyperstimulation syndrome in GnRH antagonist versus GnRH agonist protocol: RCT including 1050 first IVF/ICSI cycles.
    Toftager M; Bogstad J; Bryndorf T; Løssl K; Roskær J; Holland T; Prætorius L; Zedeler A; Nilas L; Pinborg A
    Hum Reprod; 2016 Jun; 31(6):1253-64. PubMed ID: 27060174
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modified natural cycle versus controlled ovarian hyperstimulation IVF: a cost-effectiveness evaluation of three simulated treatment scenarios.
    Groen H; Tonch N; Simons AH; van der Veen F; Hoek A; Land JA
    Hum Reprod; 2013 Dec; 28(12):3236-46. PubMed ID: 24166594
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical efficacy of highly purified urinary FSH versus recombinant FSH in volunteers undergoing controlled ovarian stimulation for in vitro fertilization: a randomized, multicenter, investigator-blind trial.
    Baker VL; Fujimoto VY; Kettel LM; Adamson GD; Hoehler F; Jones CE; Soules MR
    Fertil Steril; 2009 Apr; 91(4):1005-11. PubMed ID: 18367182
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Does metformin affect the ovarian response to gonadotropins for in vitro fertilization treatment in patients with polycystic ovary syndrome and reduced ovarian reserve? A randomized controlled trial.
    Palomba S; Falbo A; Di Cello A; Cappiello F; Tolino A; Zullo F
    Fertil Steril; 2011 Nov; 96(5):1128-33. PubMed ID: 21917254
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Large, comparative, randomized double-blind trial confirming noninferiority of pregnancy rates for corifollitropin alfa compared with recombinant follicle-stimulating hormone in a gonadotropin-releasing hormone antagonist controlled ovarian stimulation protocol in older patients undergoing in vitro fertilization.
    Boostanfar R; Shapiro B; Levy M; Rosenwaks Z; Witjes H; Stegmann BJ; Elbers J; Gordon K; Mannaerts B;
    Fertil Steril; 2015 Jul; 104(1):94-103.e1. PubMed ID: 26003273
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Do poor-responder patients benefit from increasing the daily gonadotropin dose from 300 to 450 IU during controlled ovarian hyperstimulation for IVF?].
    Haas J; Zilberberg E; Kedem A; Dar S; Orvieto R
    Harefuah; 2015 Feb; 154(2):114-7, 135. PubMed ID: 25856865
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Triggering ovulation with gonadotropin-releasing hormone agonist in in vitro fertilization patients with polycystic ovaries does not cause ovarian hyperstimulation syndrome despite very high estradiol levels.
    Manzanares MA; Gómez-Palomares JL; Ricciarelli E; Hernández ER
    Fertil Steril; 2010 Mar; 93(4):1215-9. PubMed ID: 19200978
    [TBL] [Abstract][Full Text] [Related]  

  • 20. No beneficial effects of human growth hormone therapy in normal ovulatory patients with a poor ovarian response to gonadotropins.
    Levron J; Lewit N; Erlik Y; Itskovitz-Eldor J
    Gynecol Obstet Invest; 1993; 35(2):65-8. PubMed ID: 8449446
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.